knowledge -WSS

knowledge

author：explore 2025-10-01 15:29:57 - browse：8

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Alabama hospital puts IVF treatments on hold

WSS

How to increase colonoscopy rates? Looks like an AI can help

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Medicare inequities exacerbate Puerto Rico’s health disparities

Cord blood banking comes at a high cost to babies

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

With trial win, GSK could get blood cancer drug back on market

focus

knowledge

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Novavax promises a turnaround & Lilly roils the obesity market

Woman returns to dialysis after doctors remove transplanted pig kidney

Continuity nursing helped my family in our darkest PICU moments

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

State Dept. review finds Biden bears some blame for Afghanistan failures

Ed Silverman on new gene therapies, biosimilars, coffee, and more

leisure time

The Pandemic Treaty must support building strong health systems

PBM reform efforts get punted in Congress

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

ASCO: AstraZeneca says CAR

PBM reform efforts get punted in Congress

A solution to the after

knowledge

entertainment

hotspot

leisure time